Indeed, the expression of IDO was significantly increased in the tumor microenvironment (TME) and tumor‐draining lymph node (TDLN) after treatment with TLR 7/8 agonists (TLR 7/8a), suggesting that IDO was induced to counterbalance the increased inflammatory conditions. The gene discussed is IDO1; the disease is neoplasm.